Oncolytic Viruses: The Best is Yet to Come

Author(s): Chantal G. Lemay, Brian A. Keller, Robert E. Edge, Masato Abei, John C. Bell*

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 2 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Oncolytic viruses are a promising anti-cancer platform, achieving significant pre-clinical and clinical milestones in recent years. A full arsenal of selective, safe, and effective viruses has been developed with some emerging pre-clinical research focusing on optimizing these therapies in the face of remaining challenges, both in the bloodstream and in the tumour microenvironment. Herein we discuss the recent progress in pre-clinical virotherapy research to address these challenges, with special focus on innovative strategies that seek to complement the current strengths of virotherapy, ensuring an optimal multi-faceted attack on cancer. This review highlights the research areas that we believe provide the most potential to increase the efficacy of this exciting biotherapy platform: cell carriers, tumour vascular destruction, microenvironment modulation, combination therapies, and virus-mediated anti-tumour immune responses.

Keywords: Cancer therapy, combination therapy, immunity, oncolytic viruses, tumour microenvironment, virotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 05 February, 2017
Page: [109 - 123]
Pages: 15
DOI: 10.2174/1568009617666170206111609
Price: $65

Article Metrics

PDF: 57